Cellycel personal page - To The Moon

Cellycel

No personal profile

4Follow

3Followers

0Topic

0Badge

2021-07-22

Nice

Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO

2021-06-05

Nice

Sorry, the original content has been removed

2021-05-23

Nice!

Snap buys WaveOptics, a company that makes parts for augmented reality glasses, in $500 million deal

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582080395234163","uuid":"3582080395234163","gmtCreate":1618986499781,"gmtModify":1618986499781,"name":"Cellycel","pinyin":"cellycel","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":4,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":172068591,"gmtCreate":1626921396413,"gmtModify":1703480630979,"author":{"id":"3582080395234163","authorId":"3582080395234163","name":"Cellycel","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582080395234163","idStr":"3582080395234163"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172068591","repostId":"2153643390","repostType":4,"repost":{"id":"2153643390","kind":"news","pubTimestamp":1626919402,"share":"https://ttm.financial/m/news/2153643390?lang=&edition=fundamental","pubTime":"2021-07-22 10:03","market":"us","language":"en","title":"Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643390","media":"Bloomberg","summary":"(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is consideri","content":"<p>(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.</p>\n<p>The company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.</p>\n<p>Hummingbird could seek to raise about $200 million to $300 million in a share sale, which could take place as soon as later this year, the people said. The company is leaning toward the U.S. as a preferred listing venue, they added.</p>\n<p>It plans to use part of the proceeds to support business expansion, the people said. No final decision has been made, the people said. Details such as the type of fundraising, size and timing could still change, they said.</p>\n<p>Hummingbird Bioscience is unable to comment on the speculation regarding an IPO, it said in an emailed statement in response to a Bloomberg News query. As a growth-stage biotech company, Hummingbird is continuously exploring future financing options, and remains focused on delivering against its development program and strategy, it said.</p>\n<p>The company focuses on developing treatments in areas such as oncology and autoimmunity in collaboration with global partners in academia and industry, according to its website.</p>\n<p>Hummingbird raised $125 million in a series C financing round in May led by Novo Holdings, the Danish private investor which is the controlling shareholder in Novo Nordisk A/S, the world’s largest maker of insulin. Other investors include Amgen Ventures, the venture capital arm of U.S. biotech giant Amgen Inc.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进"},"source_url":"https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2153643390","content_text":"(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.\nThe company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.\nHummingbird could seek to raise about $200 million to $300 million in a share sale, which could take place as soon as later this year, the people said. The company is leaning toward the U.S. as a preferred listing venue, they added.\nIt plans to use part of the proceeds to support business expansion, the people said. No final decision has been made, the people said. Details such as the type of fundraising, size and timing could still change, they said.\nHummingbird Bioscience is unable to comment on the speculation regarding an IPO, it said in an emailed statement in response to a Bloomberg News query. As a growth-stage biotech company, Hummingbird is continuously exploring future financing options, and remains focused on delivering against its development program and strategy, it said.\nThe company focuses on developing treatments in areas such as oncology and autoimmunity in collaboration with global partners in academia and industry, according to its website.\nHummingbird raised $125 million in a series C financing round in May led by Novo Holdings, the Danish private investor which is the controlling shareholder in Novo Nordisk A/S, the world’s largest maker of insulin. Other investors include Amgen Ventures, the venture capital arm of U.S. biotech giant Amgen Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112662438,"gmtCreate":1622866751524,"gmtModify":1704192747486,"author":{"id":"3582080395234163","authorId":"3582080395234163","name":"Cellycel","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582080395234163","idStr":"3582080395234163"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112662438","repostId":"1162130057","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":133283398,"gmtCreate":1621753502014,"gmtModify":1704362105878,"author":{"id":"3582080395234163","authorId":"3582080395234163","name":"Cellycel","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582080395234163","idStr":"3582080395234163"},"themes":[],"htmlText":"Nice!&nbsp;","listText":"Nice!&nbsp;","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/133283398","repostId":"1139227166","repostType":4,"repost":{"id":"1139227166","kind":"news","pubTimestamp":1621604641,"share":"https://ttm.financial/m/news/1139227166?lang=&edition=fundamental","pubTime":"2021-05-21 21:44","market":"us","language":"en","title":"Snap buys WaveOptics, a company that makes parts for augmented reality glasses, in $500 million deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1139227166","media":"CNBC","summary":"KEY POINTS\n\nSnap is acquiring WaveOptics, a company that creates lenses and other parts that are use","content":"<div>\n<p>KEY POINTS\n\nSnap is acquiring WaveOptics, a company that creates lenses and other parts that are used in augmented reality glasses.\nThe acquisition will give Snap many of the components to create ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/21/snap-buys-augmented-reality-company-waveoptics-in-500-million-deal.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Snap buys WaveOptics, a company that makes parts for augmented reality glasses, in $500 million deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSnap buys WaveOptics, a company that makes parts for augmented reality glasses, in $500 million deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-21 21:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/21/snap-buys-augmented-reality-company-waveoptics-in-500-million-deal.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nSnap is acquiring WaveOptics, a company that creates lenses and other parts that are used in augmented reality glasses.\nThe acquisition will give Snap many of the components to create ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/21/snap-buys-augmented-reality-company-waveoptics-in-500-million-deal.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc"},"source_url":"https://www.cnbc.com/2021/05/21/snap-buys-augmented-reality-company-waveoptics-in-500-million-deal.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1139227166","content_text":"KEY POINTS\n\nSnap is acquiring WaveOptics, a company that creates lenses and other parts that are used in augmented reality glasses.\nThe acquisition will give Snap many of the components to create glasses that people can wear and then see computer-generated imagery overlaid on top of the real world.\nSnap unveiled its first augmented reality Spectacles glasses on Thursday.\n\nSnap is acquiring WaveOptics, a company that creates lenses and other parts that are used in augmented reality glasses. The acquisition will give Snap many of the components to create glasses that people can wear and then see computer-generated imagery overlaid on top of the real world.\nSnap confirmed to CNBC Friday the deal is worth about $500 million in cash and stock, with about half paid upfront in stock. Snap will pay the remainder in cash or stock in two years. The Verge first reported on the acquisition.\nShares of Snap were down about 1% on Friday morning.\nSnap unveiled its first augmented reality Spectacles glasses on Thursday, but they aren’t for sale. Instead, Snapchat is giving them to creators first, as it presumably continues to fine-tune the glasses until it’s ready to sell a version to consumers. The new Spectacles use lenses developed by WaveOptics.\nThey’re a first step in the race to AR glasses among tech companies, however, with other firms like Apple and Facebook working on similar products. Developers will need to make compelling apps for the glasses, which currently only have about 30 minutes of battery life.\nSnap is well on its way to having lots of compelling augmented reality apps, however, since AR is already a big part of the Snapchat app. Snapchat users can already take advantage of AR for shopping, creating video and photo filters and more through their phones.\nSnap’s AR glasses are different than some AR productss that already exist, like Microsoft’s HoloLens 2, which is much larger and looks more like a headset than a set of glasses.\nWaveOptics creates some of the parts that people look through while wearing the glasses, like waveguides, which are sort of like little windows you look through that show the computer-generated imagery, and projectors that direct light at the waveguides. It also makes and sells full solutions, called modules, which include the waveguides and projectors mounted to frames.","news_type":1},"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":133283398,"gmtCreate":1621753502014,"gmtModify":1704362105878,"author":{"id":"3582080395234163","authorId":"3582080395234163","name":"Cellycel","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582080395234163","authorIdStr":"3582080395234163"},"themes":[],"htmlText":"Nice!&nbsp;","listText":"Nice!&nbsp;","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/133283398","repostId":"1139227166","repostType":4,"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172068591,"gmtCreate":1626921396413,"gmtModify":1703480630979,"author":{"id":"3582080395234163","authorId":"3582080395234163","name":"Cellycel","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582080395234163","authorIdStr":"3582080395234163"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172068591","repostId":"2153643390","repostType":4,"repost":{"id":"2153643390","kind":"news","pubTimestamp":1626919402,"share":"https://ttm.financial/m/news/2153643390?lang=&edition=fundamental","pubTime":"2021-07-22 10:03","market":"us","language":"en","title":"Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643390","media":"Bloomberg","summary":"(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is consideri","content":"<p>(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.</p>\n<p>The company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.</p>\n<p>Hummingbird could seek to raise about $200 million to $300 million in a share sale, which could take place as soon as later this year, the people said. The company is leaning toward the U.S. as a preferred listing venue, they added.</p>\n<p>It plans to use part of the proceeds to support business expansion, the people said. No final decision has been made, the people said. Details such as the type of fundraising, size and timing could still change, they said.</p>\n<p>Hummingbird Bioscience is unable to comment on the speculation regarding an IPO, it said in an emailed statement in response to a Bloomberg News query. As a growth-stage biotech company, Hummingbird is continuously exploring future financing options, and remains focused on delivering against its development program and strategy, it said.</p>\n<p>The company focuses on developing treatments in areas such as oncology and autoimmunity in collaboration with global partners in academia and industry, according to its website.</p>\n<p>Hummingbird raised $125 million in a series C financing round in May led by Novo Holdings, the Danish private investor which is the controlling shareholder in Novo Nordisk A/S, the world’s largest maker of insulin. Other investors include Amgen Ventures, the venture capital arm of U.S. biotech giant Amgen Inc.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进"},"source_url":"https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2153643390","content_text":"(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.\nThe company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.\nHummingbird could seek to raise about $200 million to $300 million in a share sale, which could take place as soon as later this year, the people said. The company is leaning toward the U.S. as a preferred listing venue, they added.\nIt plans to use part of the proceeds to support business expansion, the people said. No final decision has been made, the people said. Details such as the type of fundraising, size and timing could still change, they said.\nHummingbird Bioscience is unable to comment on the speculation regarding an IPO, it said in an emailed statement in response to a Bloomberg News query. As a growth-stage biotech company, Hummingbird is continuously exploring future financing options, and remains focused on delivering against its development program and strategy, it said.\nThe company focuses on developing treatments in areas such as oncology and autoimmunity in collaboration with global partners in academia and industry, according to its website.\nHummingbird raised $125 million in a series C financing round in May led by Novo Holdings, the Danish private investor which is the controlling shareholder in Novo Nordisk A/S, the world’s largest maker of insulin. Other investors include Amgen Ventures, the venture capital arm of U.S. biotech giant Amgen Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112662438,"gmtCreate":1622866751524,"gmtModify":1704192747486,"author":{"id":"3582080395234163","authorId":"3582080395234163","name":"Cellycel","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582080395234163","authorIdStr":"3582080395234163"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112662438","repostId":"1162130057","repostType":4,"repost":{"id":"1162130057","kind":"news","pubTimestamp":1622862397,"share":"https://ttm.financial/m/news/1162130057?lang=&edition=fundamental","pubTime":"2021-06-05 11:06","market":"us","language":"en","title":"The S&P 500 would be below 1,600 without these 3 pillars and those supports are now weakening","url":"https://stock-news.laohu8.com/highlight/detail?id=1162130057","media":"MarketWatch","summary":"Investors may need to consider private equity to capture the returns that publicly traded stocks hav","content":"<p>Investors may need to consider private equity to capture the returns that publicly traded stocks have provided</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ab21eb0dc365f342dd26c49af9020305\" tg-width=\"1260\" tg-height=\"840\"><span>GETTY IMAGES</span></p>\n<p>Stock prices can’t indefinitely grow faster than the economy. This provides a crucial reality check for U.S. stock-market bulls, many of whom believe stocks can continue outperforming the U.S. economy in perpetuity. Over the past decade, for example, the S&amp;P 500SPX,+0.88%on an inflation-adjusted total-return basis has outperformed real U.S. GDP by an annualized margin of 11.9% to 2.0%.</p>\n<p>Going forward, it could be the other way around, according to an argument advanced some years ago by Robert Arnott, founder of&nbsp;Research Affiliates, and William Bernstein, co-principal at&nbsp;Efficient Frontier Advisors. They pointed out that a portion of economic growth is attributable to non-public companies, such as startups and the like — a category they refer to as “entrepreneurial capitalism.”</p>\n<p>By definition, economic growth that non-public companies generate will not show up in the stock market— which only reflects the performance of publicly traded corporations. Arnott and Bernstein estimate that share prices historically have grown about two annualized percentage points slower than the overall economy.</p>\n<p>Such slippage has dire implications for the U.S. stock market’s future return. But I want to first discuss why the stock market’s stunning performance over the past decade was not due to economic growth. Instead, the bulk of that performance was due to three factors:</p>\n<ul>\n <li>Valuation changes: The S&amp;P 500’s price/earnings ratio has doubled over the past decade.</li>\n <li>Increasing profit margins: The S&amp;P 500’s operating margin over the past four quarters has averaged nearly two percentage points higher than it was a decade ago, according to data from Howard Silverblatt, senior index analyst at S&amp;P Dow Jones Indices.</li>\n <li>Net buybacks: Over the past decade corporations have repurchased more shares than new shares they have issued. This has reduced the number of shares outstanding, and increased earnings per share.</li>\n</ul>\n<p>To appreciate the impact of these three factors, consider that the S&amp;P 500 now would trade below 1,600 if there had been no change at all over the past decade with each of these three dimensions. While the chance of such a perfect storm is so low that you might be inclined to dismiss it out of hand, Bernstein said in an interview that he wouldn’t discount the possibility.</p>\n<p><b>Projecting the future</b></p>\n<p>The picture this analysis paints about the U.S. stock market’s future isn’t pretty, assuming the U.S. economy grows at the same pace over the next decade as the last. In that case, the only way the market can produce annualized returns greater than the low single-digits is for the P/E ratio and profit margins to continue rising or for net buybacks to continue reducing the number of shares outstanding — or for some combination of these three factors to occur.</p>\n<p>More likely, these three tailwinds will become headwinds. P/E ratios&nbsp;already are at or near the high end of their historical distribution, and they can’t go up forever. Profit margins also are at or near record levels and,as I argued earlier this week, there are good reasons to expect those margins to decline in coming years. While it’s possible that buybacks will outpace share issuance in coming years, that’s hardly a sure bet. Over the past 12 months, for example, there have been negative net buybacks — i.e. more shares have been issued than repurchased. In fact, Arnott pointed out in an email, for most of U.S. stock market history net buybacks have been negative.</p>\n<p>One can also wonder if an even-greater share of economic growth in coming years will accrue to non-public equity. Andrew Karolyi, dean of Cornell University’s SC Johnson College of Business, said in an interview that private equity now plays a much bigger role than in the past. One possible future, he said, is that the growth of the public stock market lags that of the overall economy by an increasing amount.</p>\n<p>One measure of the declining economic importance of the public corporation is the decreasing number of publicly traded companies, as reflected in the chart below. This decline has been overlooked by many on Wall Street, given their focus on the red-hot IPO market. But, as Karolyi pointed out, even as more companies are coming to market, there have also been an increasing number of delistings.</p>\n<p><img src=\"https://static.tigerbbs.com/3de45fd68cb24b2bdf2791d1f6b9fac0\" tg-width=\"1260\" tg-height=\"922\"></p>\n<p>For example, according to Refinitiv, through the end of May 2021 there was more than $1.6 trillion in domestic M&amp;A activity, almost 50% higher than the previous calendar year that held the record for the most M&amp;A activity for the first five months. We need to focus on both IPOs and delistings, Karolyi argued, just as demographers can only analyze population trends by focusing on births and deaths.</p>\n<p>“The role of publicly traded corporations in the overall economy may be changing,” Karolyi said. Their possible life cycle paths are expanding to include many that don’t end in becoming publicly traded, for example, or waiting much longer before doing so. Given the abundant liquidity in the private equity market, he added, it may very well become the preferred exit strategy for many companies that previously would have gone public.</p>\n<p>The bottom line? The past decade was extraordinary for publicly traded U.S. stocks. Don’t expect that to continue indefinitely.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The S&P 500 would be below 1,600 without these 3 pillars and those supports are now weakening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe S&P 500 would be below 1,600 without these 3 pillars and those supports are now weakening\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-05 11:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/the-s-p-500-would-be-below-1-600-without-these-3-pillars-and-those-supports-are-now-weakening-11622781972?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors may need to consider private equity to capture the returns that publicly traded stocks have provided\nGETTY IMAGES\nStock prices can’t indefinitely grow faster than the economy. This provides ...</p>\n\n<a href=\"https://www.marketwatch.com/story/the-s-p-500-would-be-below-1-600-without-these-3-pillars-and-those-supports-are-now-weakening-11622781972?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/the-s-p-500-would-be-below-1-600-without-these-3-pillars-and-those-supports-are-now-weakening-11622781972?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162130057","content_text":"Investors may need to consider private equity to capture the returns that publicly traded stocks have provided\nGETTY IMAGES\nStock prices can’t indefinitely grow faster than the economy. This provides a crucial reality check for U.S. stock-market bulls, many of whom believe stocks can continue outperforming the U.S. economy in perpetuity. Over the past decade, for example, the S&P 500SPX,+0.88%on an inflation-adjusted total-return basis has outperformed real U.S. GDP by an annualized margin of 11.9% to 2.0%.\nGoing forward, it could be the other way around, according to an argument advanced some years ago by Robert Arnott, founder of Research Affiliates, and William Bernstein, co-principal at Efficient Frontier Advisors. They pointed out that a portion of economic growth is attributable to non-public companies, such as startups and the like — a category they refer to as “entrepreneurial capitalism.”\nBy definition, economic growth that non-public companies generate will not show up in the stock market— which only reflects the performance of publicly traded corporations. Arnott and Bernstein estimate that share prices historically have grown about two annualized percentage points slower than the overall economy.\nSuch slippage has dire implications for the U.S. stock market’s future return. But I want to first discuss why the stock market’s stunning performance over the past decade was not due to economic growth. Instead, the bulk of that performance was due to three factors:\n\nValuation changes: The S&P 500’s price/earnings ratio has doubled over the past decade.\nIncreasing profit margins: The S&P 500’s operating margin over the past four quarters has averaged nearly two percentage points higher than it was a decade ago, according to data from Howard Silverblatt, senior index analyst at S&P Dow Jones Indices.\nNet buybacks: Over the past decade corporations have repurchased more shares than new shares they have issued. This has reduced the number of shares outstanding, and increased earnings per share.\n\nTo appreciate the impact of these three factors, consider that the S&P 500 now would trade below 1,600 if there had been no change at all over the past decade with each of these three dimensions. While the chance of such a perfect storm is so low that you might be inclined to dismiss it out of hand, Bernstein said in an interview that he wouldn’t discount the possibility.\nProjecting the future\nThe picture this analysis paints about the U.S. stock market’s future isn’t pretty, assuming the U.S. economy grows at the same pace over the next decade as the last. In that case, the only way the market can produce annualized returns greater than the low single-digits is for the P/E ratio and profit margins to continue rising or for net buybacks to continue reducing the number of shares outstanding — or for some combination of these three factors to occur.\nMore likely, these three tailwinds will become headwinds. P/E ratios already are at or near the high end of their historical distribution, and they can’t go up forever. Profit margins also are at or near record levels and,as I argued earlier this week, there are good reasons to expect those margins to decline in coming years. While it’s possible that buybacks will outpace share issuance in coming years, that’s hardly a sure bet. Over the past 12 months, for example, there have been negative net buybacks — i.e. more shares have been issued than repurchased. In fact, Arnott pointed out in an email, for most of U.S. stock market history net buybacks have been negative.\nOne can also wonder if an even-greater share of economic growth in coming years will accrue to non-public equity. Andrew Karolyi, dean of Cornell University’s SC Johnson College of Business, said in an interview that private equity now plays a much bigger role than in the past. One possible future, he said, is that the growth of the public stock market lags that of the overall economy by an increasing amount.\nOne measure of the declining economic importance of the public corporation is the decreasing number of publicly traded companies, as reflected in the chart below. This decline has been overlooked by many on Wall Street, given their focus on the red-hot IPO market. But, as Karolyi pointed out, even as more companies are coming to market, there have also been an increasing number of delistings.\n\nFor example, according to Refinitiv, through the end of May 2021 there was more than $1.6 trillion in domestic M&A activity, almost 50% higher than the previous calendar year that held the record for the most M&A activity for the first five months. We need to focus on both IPOs and delistings, Karolyi argued, just as demographers can only analyze population trends by focusing on births and deaths.\n“The role of publicly traded corporations in the overall economy may be changing,” Karolyi said. Their possible life cycle paths are expanding to include many that don’t end in becoming publicly traded, for example, or waiting much longer before doing so. Given the abundant liquidity in the private equity market, he added, it may very well become the preferred exit strategy for many companies that previously would have gone public.\nThe bottom line? The past decade was extraordinary for publicly traded U.S. stocks. Don’t expect that to continue indefinitely.","news_type":1},"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}